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2010;28(7):1106–11.fter reading Dr. Zietman’s thought-provoking paper1 as arti-
le in press, I believe the following comments will add some
dditional context to the “debate”:
. Consider that another reason the “majority of cases” being
treated are prostate cases is not only because of the time
and ﬁnancial requirements, but because of the limitations
of technology-until recently most proton centers found it
difﬁcult to treat large, complex ﬁeld shapes. Imagine if
IMRT  had been limited to a <20 cm ﬁeld size when ﬁrst
introduced? I strongly suspect we  would have seen a similar
case mix  predominating.
. PBT plans do contain some uncertainties-as do photon
plans. Clinical experience has validated the 1.1 RBE, else
the rate of Gr ≥ 3 complications in the high-dose arm of
PROG 9509 would have been far higher.2 Ongoing improve-
ments in PBT planning (widespread introduction of Monte
Carlo calculations) will substantially mitigate these uncer-
tainties.
. Neutron production by passive-scattered proton treatment
is at worst no greater than that seen in IMRT3; this disparity
between the modalities increases with increasing ﬁeld size.
. It is not impossible to “Turn back the clock” on IMRT, par-
ticularly since its use was not validated in a randomized
fashion before its widespread clinical adaptation-it is sim-
ply a question of intellectual and political will. Considering
the far greater economic impact that IMRT is having on
current annual radiation oncology expenditures than PBT,
it would be far more  cost-effective to sharply curtail IMRT
use than to concentrate solely on PBT. To be scientiﬁcally
consistent, IMRT  should be subjected to the same stan-
dards of evidence as some insist on being met  by PBT, and
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ttp://dx.doi.org/10.1016/j.rpor.2013.09.001should require the same level of validation i.e., a Phase III
prospective randomized trial of IMRT vs. 3-DCRT, IMRT  vs.
brachytherapy, etc.
5. IMPT is to protons what IMRT was to X-rays, yet the current
PBT–IMRT randomized trial does not utilize IMPT but older,
passive-scatter PBT which treats more  normal tissue than
IMPT, thus any conclusions emanating from the ongoing
trial may not accurately reﬂect the clinical beneﬁts which
can be obtained with IMPT.
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